Dose-response study of dapiprazole HC1 in the reversal of mydriasis induced by 2.5% phenylephrine

Journal of Ocular Pharmacology and Therapeutics

Volumn 13, Issue 4, 1997, Pages 297-302

  Hogan, Tammy S ^a   Mcdaniel, Danna D ^a   Bartlett, Jimmy D ^a   Hart, Kathryn K ^b   Paggiarino, Dario A ^c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b DATA   (United States)

^c Università Politecnica delle Marche ACRAF Gruppo Angelini   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPIPRAZOLE; PHENYLEPHRINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG COST; DRUG EFFECT; DRUG HALF LIFE; DRUG TOLERANCE; FEMALE; HUMAN; MALE; MYDRIASIS; NORMAL HUMAN; PUPIL; TOPICAL DRUG ADMINISTRATION;

EID: 0030765676     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.1997.13.297     Document Type: Article

References (15)

1. Iugho, N. Ocular effects of topical application of dapiprazole in man. Glaucoma 6:110-116, 1984.
2. Reibaldi, A. A new alpha-blocking agent. Glaucoma 6:255-257, 1984.
3. Brogliatti, B., Rolle, T., Messelod, M. and Carenini, B.B. A new alpha blocking agent in treatment of glaucoma: Dapiprazole Glaucoma 7:232-236, 1985.
4. Prosdocimo, G. and De Marco, D. Intraocular dapiprazole to reverse mydriasis during extracapsular cataract extraction. Am. J. Ophthalmol. 105:321-322, 1988.
5. Shell, J.W. Pharmacokinetics of topically applied ophthalmic drugs. Surv. Ophthalmol. 26:207-218, 1982.
6. Doughty, M.J. and Lyle, W.M. A review of the clinical pharmacokinetics of pilocarpine, moxisylyte (thymoxamine), and dapiprazole in the reversal of diagnostic pupillary dilation. Optom. Vis. Sci. 69:358-368, 1992.
7. Nyman, N. and Reich, L. The effect of dapiprazole on accommodative amplitude in eyes dilated with 0.5% tropicamide. J. Am. Optom. Assoc. 64:625-628, 1993.
8. Laties, A.M., Veleria, P., Catanese, B., et al. Pharmacokinetics and biochemistry of dapiprazole In: Dapiprazole: A new alpha blocking agent in ophthalmology. Amsterdam: Kugler Publications, 1987, p. 7.
9. Bonomi, L., Marchini, G., De Feo, G., Piccineli, D. and Beltini, A. On the reversal of diagnostic mydriasis with dapiprazole. Curr. Ther. Res. 38:945-952, 1985.
10. Nyman, N. and Keates, E.U. Effects of dapiprazole on the reversal of pharmacologically-induced mydriasis. Optom. Vis. Sci. 67:705-709, 1990.
11. Bucci, M.G., D'Andrea, D., Bettini, A. and De Gregorio, M. Dapiprazole for the reversal of mydriasis due to tropicamide. Glaucoma 9:94-98, 1987.
12. Molinari, J.F., Johnson, M.E. and Carter, J. Dapiprazole. Clinical efficacy for counteracting tropicamide 1%. Optom. Vis. Sci. 71:319-322, 1994.
13. Johnson, M.E., Molinari, J.F. and Carter, J. Efficacy of dapiprazole with hydroxyamphetamine hydrobromide and tropicamide. J. Am. Optom. Assoc. 64:629-633, 1993.
14. Connor, C.G., Campbell, J.B. and Tirey, W.W. The clinical efficacy of Rev-Eyes in reversing the effects of pupillary dilation. J. Am. Optom. Assoc. 64:634-636, 1993.
15. Wilcox, C.S., Heiser, J.F., Crowder, A.M., et al. Comparison of the effects on pupil size and accommodation of three regimens of topical dapiprazole. Br. J. Ophthalmol. 79:544-548, 1995.